Carcinoma, Hepatocellular
Conditions
Brief summary
The radical treatment for Hepatocellular carcinoma (HCC) is surgery. However, it is only for 10 to 20% of all patients and 10 to 30% of them have relapsed every year after surgery. For an inoperable case, we can consider Liver transplantation. But there is not enough organ donor and it is very expensive. In that case, various treatment modalities for HCC (i.e., transcatheter arterial embolization \[TAE\] and percutaneous ethanol injection \[PEI\], radiofrequency ablation etc.) have become clinically available. In addition, after these treatment, radiation therapy can be conducted as a combined treatment. If it is difficult, radiation therapy can be conducted alone. In this case, radiation therapy can use fractionated stereotactic radiation therapy \[FSRT\] or 3D simulation to minimize the exposure to normal tissues. In recent years, Proton therapy is a new radiation therapy which remaining energy is released when they reach the tumor, delivering the most effective dose of radiation. The purpose of this trial is to improve the therapeutic effects by using proton therapy.
Interventions
\- Prescription dose to PTV as according to the following dose escalation schema: Dose level 1: 60 GyE /20 fx, 3GyE fraction dose, 5 days/week. Dose level 2: 66 GyE /22 fx, 3GyE fraction dose, 5 days/week. Dose level 3: 72 GyE /24 fx, 3GyE fraction dose, 5 days/week.
Sponsors
National Cancer Center, Korea
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* HCC diagnosed as: * (i) the presence of risk factors including hepatitis B or C virus and liver cirrhosis, a serum a-fetoprotein (AFP) level greater than 400 IU/ml and a radiologically compatible feature with HCC in one or more CT/MRI/angiograms * (ii) the presence of risk factors including hepatitis B or C virus and liver cirrhosis, a serum a-fetoprotein (AFP) level less than 400 IU/ml, and a radiologically compatible feature with HCC in two or more CT/MRI/angiograms or (iii) histological confirmation * HCC patients who were not prospective suitable or refused for any other treatment, such as surgery or local ablation therapy, or recurrent or residual tumor after other treatments. * Without evidence of extrahepatic metastasis * All target tumors must be encompassable within single irradiation field (12x12 cm maximum) * No previous treatment to target tumors by other forms of RT * Digestive tract not in contact with clinical target volume * Liver function of Child-Pugh class A or B * Age of ≥ 18 years * Performance status of 0 to 2 on the Eastern Cooperative Oncology Group (ECOG) score * WBC count ≥ 2,000/mm3; hemoglobin level ≥ 7.5 g/dL; platelet count ≥ 25,000/mm3; and adequate hepatic function (total bilirubin ≤ 3.0 mg/dL; AST and ALT \< 5.0× upper limit of normal; no ascites) * No serious comorbidities other than liver cirrhosis
Exclusion criteria
* Evidence of extrahepatic metastasis * Age \< 18 years * Liver function of Child-Pugh class C * Previous history of other forms of RT adjacent to target tumors * Poor performance status of 3 to 4 on the Eastern Cooperative Oncology Group (ECOG) score * Diffusely infiltrating tumor which is difficult to define the gross tumor volume accurately * Multicentric HCCs, except for those with the following two conditions: * (i) multinodular aggregating HCC that could be encompassed by single clinical target volume and within single irradiation field (15x15 cm maximum) * (ii) lesions other than targeted tumor that were judged as controlled with prior surgery and/or local ablation therapy * Digestive tract in contact with clinical target volume * Pregnant or breast feeding status * Previous history uncontrolled other malignancies within 2 years
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| all cause mortality | 2 years |
Countries
South Korea
Outcome results
None listed